1. ALLA AKTIER
  2. NYHETER
  3. SANIONA

Saniona

Nyheter Saniona Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Saniona publishes its interim report for the first quarter of 2023

MAR
Q1 2023 (2022)
Revenue was SEK 2.2 M (6.6 M)
Operating profit/loss was SEK -21.1 M (-133.2 M)
Net profit/loss was SEK -21.7 M (-133.4 M)
Basic earnings/loss per share was SEK -0.35 (-2.14)
Diluted earnings/loss per share were SEK -0.35 (-2.14)

Business highlights in Q1 2023

  • On January 17, Saniona announced successful preclinical in vivo validation for treatment of migraine in the Cephagenix joint venture program.
  • On February 25, Saniona announced that its partner Medix received favorable opinion for tesofensine for the treatment of obesity and weight management in Mexico.

Significant events after the reporting period

  • There have been no events after the reporting period.

Comments from the CEO
“Good progress on partnering negotiations and a potential approval of tesofensine in Mexico for treatment of obesity.”

For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. Saniona’s most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity by Saniona’s partner Medix. Saniona is advancing four product candidates including Tesomet™ and three ion channel modulators SAN711, SAN903 and SAN2219. Tesomet™ has progressed to mid-stage clinical trials for rare eating disorders. SAN711 has completed Phase 1 for neuropathic pain conditions. SAN903 is ready for Phase 1 for inflammatory and fibrotic disorders. SAN2219 is in preclinical development for epilepsy. Saniona has research and development partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cephagenix ApS. Saniona is based in Copenhagen, and listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

This information is information that Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-25 08:00 CEST.

Attachments
20230525 Saniona Q1 2023 (UK)

Datum 2023-05-25, kl 08:00
Källa MFN
Bifogade filer
20230525 Saniona Q1 2023 (UK)